Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ecleralimab (CSJ117) in severe uncontrolled asthma
NCT04410523Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Antibody Conjugates, Fab Fragments, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of ecleralimab in asthma, sponsored by Novartis. Started Sep 2020; status: terminated.
02
Drugs
ecleralimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04410523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410523.